Understanding how immune cells affect brain tumors
Official title: Myeloid Recruitments and their Role in Brain Tumors
Funded at Icahn School of Medicine at Mount Sinai · NIH-11074675 · Data updated 2026-11-12
This study is looking at how certain immune cells in the brain, called myeloid cells, affect the growth of glioblastoma tumors and how they respond to cancer treatments, with the goal of finding better ways to help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 15, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $604,587 |
| NIH project number | 5R01NS137631-02 |
| Project ID | NIH-11074675 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are seeking innovative treatment options.
✕Less likely to help
Patients with brain tumors other than glioblastoma may not benefit directly from this research.
What this research studies
This research investigates the role of myeloid cells, which are a type of immune cell, in the environment of brain tumors, specifically glioblastoma. It aims to understand how these cells contribute to tumor growth and the body's immune response to cancer therapies. By studying different types of myeloid cells that infiltrate tumors, the research seeks to uncover their interactions and how they can be targeted for better treatment outcomes. The approach includes using genetically-engineered mouse models that mimic human brain tumors to observe these processes in action.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve the effectiveness of treatments for brain tumors.
How similar studies have gone: Previous research has shown promise in targeting immune cells in cancer treatment, suggesting that this approach could lead to significant advancements.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hambardzumyan, Dolores — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hambardzumyan, Dolores
Related research
Other NIH-funded projects on the same topics.
-
ONC206 for children with brain tumors: a first-in-children trial
A first-in-children trial will test the safety and early signs of effectiveness of ONC206, taken by mouth, in kids with malignant brain tumors like diffuse midline gliomas.
-
ONC206 for children with malignant brain tumors
A first-in-children trial tests the safety and early effectiveness of a pill that can cross the brain barrier to treat pediatric brain tumors.
-
ONC206 for children with dangerous brain tumors
A first-in-children study tests the safety and early effectiveness of an oral drug, ONC206, for kids with high-risk brain tumors that have spread or recurred.
-
Oral bacteria and brain metastasis: how the mouth may influence brain tumors
A study exploring how oral microbes may affect brain metastases and patient outcomes, with potential to guide new microbiome-based approaches.
-
Bioengineered brain barrier chip to improve drug screening for brain tumors
A small, patient-friendly brain barrier chip is being developed to test drugs for glioblastoma more accurately before they reach clinical trials.
-
Understanding how epigenetic changes drive pediatric brain tumor recurrence and how reversing them could help
A pediatric brain cancer research project is exploring how an epigenetic change (H3K27M) and tumor environment contribute to tumor coming back, using a reversible mouse model to study potential ways to prevent recurrence.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.